A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. - Croden, J.; Garcia-Manero, G.; Chien, K.; DiNardo, C.; Borthakur, G.; Hammond, D.; Bose, P.; Short, N.; Romero, L.; Shneider, H.; Hatfield, M.; Pierce, S.; et al. (Leukemia & Lymphoma, 2026)